JP2024502471A - ピーナッツアレルギーを治療するための方法およびil-4rアンタゴニストを投与することによってピーナッツアレルゲン特異的免疫療法を増強する方法 - Google Patents

ピーナッツアレルギーを治療するための方法およびil-4rアンタゴニストを投与することによってピーナッツアレルゲン特異的免疫療法を増強する方法 Download PDF

Info

Publication number
JP2024502471A
JP2024502471A JP2023541519A JP2023541519A JP2024502471A JP 2024502471 A JP2024502471 A JP 2024502471A JP 2023541519 A JP2023541519 A JP 2023541519A JP 2023541519 A JP2023541519 A JP 2023541519A JP 2024502471 A JP2024502471 A JP 2024502471A
Authority
JP
Japan
Prior art keywords
dose
antagonist
peanut
seq
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502471A5 (cg-RX-API-DMAC7.html
Inventor
ジェイミー・エム・オレンゴ
アレン・ラディン
マルセラ・ルディ
エリベルト・シュタウディンガー
チウファン・ワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2024502471A publication Critical patent/JP2024502471A/ja
Publication of JP2024502471A5 publication Critical patent/JP2024502471A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023541519A 2021-01-08 2022-01-07 ピーナッツアレルギーを治療するための方法およびil-4rアンタゴニストを投与することによってピーナッツアレルゲン特異的免疫療法を増強する方法 Pending JP2024502471A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163135238P 2021-01-08 2021-01-08
US63/135,238 2021-01-08
EP21315241.6 2021-11-10
EP21315241 2021-11-10
PCT/US2022/011643 WO2022150605A1 (en) 2021-01-08 2022-01-07 Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist

Publications (2)

Publication Number Publication Date
JP2024502471A true JP2024502471A (ja) 2024-01-19
JP2024502471A5 JP2024502471A5 (cg-RX-API-DMAC7.html) 2025-01-15

Family

ID=80034850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541519A Pending JP2024502471A (ja) 2021-01-08 2022-01-07 ピーナッツアレルギーを治療するための方法およびil-4rアンタゴニストを投与することによってピーナッツアレルゲン特異的免疫療法を増強する方法

Country Status (9)

Country Link
US (1) US20220220211A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274609A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024502471A (cg-RX-API-DMAC7.html)
KR (1) KR20230130681A (cg-RX-API-DMAC7.html)
AU (1) AU2022206434A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204515A1 (cg-RX-API-DMAC7.html)
IL (1) IL304240A (cg-RX-API-DMAC7.html)
MX (1) MX2023007945A (cg-RX-API-DMAC7.html)
WO (1) WO2022150605A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
KR102872485B1 (ko) 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによるアトピー性皮膚炎の治療方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521713A (ja) * 2013-06-04 2016-07-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Il−4r阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法
JP2019531273A (ja) * 2016-09-01 2019-10-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Il−4rアンタゴニストを投与することによりアレルギーを予防又は処置するための方法
JP2022543815A (ja) * 2019-08-05 2022-10-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
MX2015010315A (es) 2013-03-14 2016-04-13 Aimmune Therapeutics Inc Fabricacion de formulaciones de mani para desensibilizacion oral.
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
EP4406975A3 (en) * 2018-06-14 2024-11-13 Ajinomoto Co., Inc. Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
KR20210143246A (ko) * 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521713A (ja) * 2013-06-04 2016-07-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Il−4r阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法
JP2019531273A (ja) * 2016-09-01 2019-10-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Il−4rアンタゴニストを投与することによりアレルギーを予防又は処置するための方法
JP2022543815A (ja) * 2019-08-05 2022-10-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO EVALUATE EFFICACY AND SAFETY, JPN6026007786, 20 August 2020 (2020-08-20), ISSN: 0005807821 *
J ALLERGY CLIN IMMUNOL, vol. vol. 147(4), JPN6026007787, 15 December 2020 (2020-12-15), pages 1381 - 1392, ISSN: 0005807822 *

Also Published As

Publication number Publication date
KR20230130681A (ko) 2023-09-12
US20220220211A1 (en) 2022-07-14
CA3204515A1 (en) 2022-07-14
EP4274609A1 (en) 2023-11-15
AU2022206434A1 (en) 2023-08-24
MX2023007945A (es) 2023-09-21
WO2022150605A1 (en) 2022-07-14
IL304240A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
JP7836754B2 (ja) Il-4rアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
JP7659500B2 (ja) アレルギーを治療するためのil-4/il-13経路阻害剤と形質細胞除去の組み合わせ
AU2019279946B2 (en) Methods for treating atopic dermatitis by administering an IL-4R antagonist
US20220220211A1 (en) Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
RU2679920C2 (ru) Способы лечения аллергии и повышения эффективности аллерген-специфической иммунотерапии путем введения ингибитора ил-4р
IL265104B2 (en) Methods for preventing or treating allergy by administering an agonist for IL-4R
US10935554B2 (en) Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
KR20230030573A (ko) 항-bet v1 항체를 사용하여 알러지를 치료하는 방법
JP2024539148A (ja) Il-4rアンタゴニストを投与することによって結節性痒疹を治療する方法
CN118355034A (zh) 施用il-4/il-13拮抗剂以减弱特应性进程的方法
WO2025165851A1 (en) Methods of treating allergy using anti-bet v 1 antibodies
CA3185718A1 (en) Treatment of food allergy using anti-ige antibodies
RU2833729C2 (ru) Способы лечения аллергии и усиления аллерген-специфической иммунотерапии путем введения антагониста il-4r
CN116887858A (zh) 通过施用il-4r拮抗剂治疗花生过敏并增强花生过敏原特异性免疫疗法的方法
KR102284244B1 (ko) Il-4r 길항제 투여로 아토피성 피부염을 치료하는 방법
AU2017321682B2 (en) Methods for preventing or treating allergy by administering an IL-4R antagonist
RU2789047C2 (ru) Способы лечения аллергии и повышения эффективности аллерген- специфической иммунотерапии путем введения ингибитора ил-4р
EA049619B1 (ru) Способы лечения аллергии с применением антител к bet v 1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260529